Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | SYNJ2 | O15056 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5309859 | 0.98 | L3MBTL1 (0.55) | L3MBTL1MAPTPOLBGAATYR | |
| SCHEMBL5309856 | 0.98 | L3MBTL1 (0.55) | L3MBTL1MAPTPOLBGAATYR | |
| SCHEMBL18392791 | 0.80 | L3MBTL1 (0.39) | L3MBTL1MAPTPOLBGAATYR | |
| SCHEMBL18385939 | 0.80 | L3MBTL1 (0.39) | L3MBTL1MAPTPOLBGAATYR | |
| SCHEMBL20381805 | 0.80 | L3MBTL1 (0.39) | L3MBTL1MAPTPOLBGAATYR | |
| SCHEMBL25222379 | 0.80 | L3MBTL1 (0.39) | L3MBTL1MAPTPOLBGAATYR | |
| SCHEMBL25585820 | 0.80 | L3MBTL1 (0.39) | L3MBTL1MAPTPOLBGAATYR | |
| SCHEMBL7149877 | 0.79 | L3MBTL1 (0.53) | L3MBTL1MAPTPOLBGAATYR | |
| SCHEMBL22710167 | 0.79 | L3MBTL1 (0.53) | L3MBTL1MAPTPOLBGAATYR | |
| SCHEMBL4959971 | 0.79 | L3MBTL1 (0.53) | L3MBTL1MAPTPOLBGAATYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1027359-B9 | MONOCYCLIC L-NUCLEOSIDES, ANALOGS AND USES THEREOF | RIBAPHARM INC (US) | 2003-09-17 | — | — | EP | disclosed |
| EP-1027359-B1 | MONOCYCLIC L-NUCLEOSIDES, ANALOGS AND USES THEREOF | RIBAPHARM INC (US) | 2003-04-23 | — | — | EP | disclosed |
| US-6552183-B1 | Moncyclic L-nucleosides analogs | ICN PHARMACEUTICALS, INC. | 2003-04-22 | — | — | US | disclosed |
| EP-1302474-A1 | Monocyclic L-nucleosides, analogs and uses thereof | Ribapharm, Inc. (US) | 2003-04-16 | — | — | EP | disclosed |
| US-20030018186-A1 | Monocyclic L-nucleosides, analogs and uses thereof | BAUSCH HEALTH COMPANIES INC. (CA) | 2003-01-23 | — | — | US | disclosed |
| EP-1254911-A1 | Monocyclic L-nucleosides, analogs and uses thereof | ICN Pharmaceuticals, Inc. (US) | 2002-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018186-A1 | Monocyclic L-nucleosides, analogs and uses thereof | PNP, TYMP, SLC29A1 | L3MBTL1 626/4885MAPT 4250/4885POLB 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.